1 Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers Am J Surg 1998; 176: 5S-10S.
2 Kumar S, Asche HA, Parnell LN. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med 1994; 11:480-84.
3 Walters DP, Gatling W, Mullee MA. The distribution and severity of diabetic foot disease: a community study with comparison to non-diabetic group. Diabet Med 1992; 9: 354-58.
4 Ramsey SD, Newton K, Blough D. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387.
5 Henriksson F, Agardh C-D, Berne C. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000; 248: 387-396
6 Muller IS, de Grauw WJC, van Gerwen WHEM. Foot amputation and lower limb amputation in type 2 diabetic patients in Dutch primary health care. Diabetes Care 2002; 25: 570-574
7 Abbot CA, Carrington AL, Ashe H. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19: 377-84
8 Abbot CA, Vileykite L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1999; 22: 382-7.
9 Van Houtum,WH, Lavery LA, Harkless LB. The impact of diabetes-related lower extremity amputations in The Netherlands. J Diabetes Comp. 1999; 10: 325-30.
10 Witsø E, Rønningen H. Lower limb amputations: registration of all lower limb amputations performed at the University Hospital of Trondheim, Norway, 1994-1997. Prosthet Orthop Int 2001; 25: 181-85.
11 Group TG. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia: the global lower extremity amputation study group. Br J Surg 2000; 87: 328-37.
12 Spichler ERS, Spichler D, Lessa I. Capture-recapture method to estimate lower extremity amputation rates in Rio de Janeiro, Brazil. Pan Am J Public Health 2001; 19: 334-40.
13 Trautner C, Giani G, Haastert B. Unchanged incidence of lower limb amputations in a German city, 1990-1998. Diabetes Care 2001; 24: 855-59.
14 Wrobel JS, Mayfield JA, Reiber GE. Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. Diabetes Care 2001; 24: 860-64.
15 Van Houtum WH, Lavery LA. Regional variation in the incidence of diabetes-related amputation in the Netherlands Diabetes. Res Clin Pract 1996; 31: 125-32.
16 Canavan R, Connolly V, Airey CM. Risk of diabetes-related amputation in South Asians vs Europeans in the UK. Diabet Med 2002; 19: 99-104
17 Boyko EJ, Ahroni JH, Smith DG. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996; 13: 967-72.
18 Moulik P, Gill G. Mortality in diabetic patients with foot ulcers. Diabetic Foot 2002;5:51-53.
19 Lavery LA, van Houtum WH, Harkless LB. In-hospital mortality and disposition of the diabetic amputees in The Netherlands. Diabet Med 1996; 13: 192-97
20 da Silva AF, Desgranges P, Holdsworth J. The management and outcome of critical limb ischemia in diabetic patients: results of a national survey. Audit Committee of the Vascular Surgical Society of Great Britain and Ireland. Diabet Med 1996; 13: 726-28
21 Aulivola B, LoGerfo FW, Pomposelli FB. Major lower extremity amputation: outcome of a modern series. Arch Surg 2004; 139 (4): 395-9.
22 Faglia E, Favales F, Morabito A. New ulceration, new major amputation and survival rates in diabetics subjects hospitalised for foot ulceration from 1990 to 1993: a 6.5year follow-up. Diabetes Care 2001; 24: 78-83.
23 The St. Vincent Declaration, Diabet. Med. 1990; 7:360, 89
24 Stiegler H, Standl E, Frank S, Mendler G. Failure of reducing lower extremity amputation in diabetic patients: results of two subsequent population based survey 1990 and 1995 in Germany. Vasa 1998; 27 (1):10-14
25 Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputations in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med 1995; 12: 770-776
26 Holstein P, Ellitsgaard N, Olsen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. Diabetologia 2000; 43: 844-847
27 Faglia E, Dalla Paola L, Clerici G et al. Peripheral angioplasty as the first choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 2005; 6: 620-627.
28 Faglia E, Favales F, Aldeghi A. Change in major amputation rate in a center dedicated to diabetic foot care during the 1980’s: prognostic determinants for major amputation. J Diabetes Complications 1998; 12: 96-102. 29 Faglia E, Mantero M, Dalla Paola L, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive subjects. J Intern Med 2002; 252: 225-232
30 Edmonds M, Forster AVM. Reduction of major amputations in the diabetic a strategy to “take control” with conservative care as well as revascularization. Vasa 2001; 58: 6-14
31 Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992; 152:610-16
32 Apelqvist J, Bakker K, van Houtum, et al . International Consensus on the Diabetic Foot. Maastricht, the Netherlands: International Working Group on the Diabetic Foot; 1999.
33 Edmonds M. Progress in care of the diabetic foot. The Lancet 1999; 354
34 Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care; 13: 513-521
35 Wagner FW. The disvascular foot: a system for diagnosis and treatment. Foot and Ankle 1981; 2: 64-122
36 Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system: contribution of depth, infection and vascular disease to the risk of amputation. Diabetes Care 1998; 21: 855-859
37 Peters EJ, Lavery LA. Effectiveness of the diabetic foot risk classification of the International Working Group on The Diabetic Foot. Diabetes Care 2001; 24: 1442-1447
38 Litzelman DK, Slemenda CW, Langefeld CD et al. Reduction of lower extremity clinical abnormalities in patients with non insulin-dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1993; 119:36-41
39 Carrington AL, Shaw JE, van Schie CH et al. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year out come period? Diabetes Care 2002; 25:2010-2015
40 Boyko EJ, Ahroni JH, Stensel V et al. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 1999; 22: 1036-1042
41 Kastenbauer T, Sauseng S, Sokol G, et al. A prospective study of predictors for foot ulceration in type 2 diabetes. J Am Podiatr Med Assoc 2001; 91: 343-350
42 Karchmer AW, Gibbons GW. Foot infections in diabetes: evaluation and management. Curr Clin Top Infect Dis; 1994;14:1-22.
43 Remedios A, Valabhji J, Oelbaum R, Sharp P, Mitchell R. 99m Tc-nanocolloid scintigraphy for assessing osteomyelitis in diabetic neuropathic feet. Clin Radiol 1998; 53:120-5.
44 Newman LG. Imaging techniques in the diabetic foot. Clin Podiatr Med Surg 1995;12: 75-86.
45 Mushlin A, Littemberg B, and the Diagnostic Technology Assessment Consortium. Diagnosing pedal osteomyelitis. J Gen Intern Med 1994;9:1-7.
46 Elgazzar A, Abdel-Dayem H, Clark J, Maxon H. Multimodality imaging of osteomyelitis. Eur J Nucl Med 1995; 22: 1043-63.
47 Gold R, Tong D, Crim J, Seeger L. Imaging the diabetic foot. Skeletal Radiol 1995; 24: 563-71.
48 Grayson M, Gibbons G, Balogh K, Levin E, Karchmer A. probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-3.
49 Lavery LA, Vela S, Quebedeaux T, et al. Total contact casts: pressure reduction at ulcer sites and the effect on the contralateral foot. Arch Phys Med Rehabil 1997; 78: 1268-1271
50 Armstrong DG, Lavery LA, Nixon BP, et al. It is not what you put on, but what you take off: techniques for debriding and offloading the diabetic foot wound. Clin Infect Dis Aug 2004; 39:S92-S99.
51 Walker SC, Helm PA, Pullium G. Total contact casting and chronic diabetic neuropathic foot ulcerations: healing rates by wound location. Arch Phys Med Rehabil 1987;68:217-221
52 Birke JA. Healing rates of plantar ulcers in leprosy and diabetes. Lepr Rev 1992; 63: 365-374
53 Helm PA, Walker SC, Pullium G. Total contact casting in diabetic patients with neuropathic foot ulcerations. Arch Phys Med Rehabil 1984; 65: 691-693
54 Sinacore DR, Mueller MJ, Diamond JE, et al. Diabetic plantar ulcers associated with midfoot fracture due to Charcot’s arthropathy. Diabet Med 1997; 14: 46-49.
55 Lavery LA, Armstrong DG, Walker SC. Healing rates of diabetic foot ulcers associated with midfoot fracture due to Charcot’s arthropathy. Diabet Med 1997; 14: 46-49).
56 Peters EJ, Lavery LA, Armstrong DG, et al. Electric stimulation a san adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil 2001; 82: 721-725
57 Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26: 1701-1705
58 Piaggesi A, Macchiarini S, Rizzo L et al. An Off-Shelf Instant Contact Casting Device for the Management of Diabetic Foot Ulcers. Diabetes Care 2007;30: 586-590
59 Caravaggi C, Faglia E, DeGiglio R, et al. Effectiveness and safety of nonremovable fibreglass off-bearing cast versus therapeutic shoe in the treatmet of neuropathic foot ulcers. Diabetes Care 2000; 2006-12.
60 Armstrong DG, Nguyen HC, Lavery L, van Schie CHM, Boulton AJM, Harkless LB. Off loading the diabetic foot wound. Diabetes Care 2001; 24: 1019-1022
61 Piaggesi A, Viacava P, Rizzo L, et. Al. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief. Diabetes Care 2003 Nov; 26 (11):3123-8.
62 Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care 2005; 28 (3): 551-4
63 Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward a rational definition. Diabet Med 2003; 20; 329-331.
64 Blume J. Single-stage surgical treatment of non infected diabetic foot ulcers. Plas Rec Surg; 109(2):601-609.2002
65 Piaggesi A, Schipani E, et al. Conservative surgical approach versus non-surgical management of diabetic neuropathic foot ulcers. Diabet Med 1998;15(5): 412-7
66 Armstrong DG, Stacpoole-Shea S, Nguyen H, Harkless LB. Lenghtening of the Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. J Bone Joint Surg Am 1999; 81 (4): 535-8
67 Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44:2032-7
68 Sanders LJ, Fryberg RG. Charcot Foot. In Levin ME, O’Neil LW, Bowker JH, The Diabetic Foot 5th Edition. c.c. Mosby St. Louis, 1993: pp 149-180
69 Shaw JE, Boulton AJM. The Charcot foot. Foot 1995; 5:65-70
70 Cofield RH, Morrison MJ, Beabout JW, Diabetic Neuroarthropathy in the Foot: patient characteristics and patterns of radiographic change. Foot Ankle 1983; 4: 18-22
71 Young MJ, Marshall A, Adams JE, Selby PL, Boulton AJM. Osteopaenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 1995; 18: 34-38
72 Edmonds ME, Clarke MB, Newton S, Barrett J, Watkins PJ. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 1985; 57: 843-855
73 Edelson GW, Jensen JL, Kaczynski R. Identifying acute Charcot arthropathy through urinary cross-linked N-telopeptides. Diabetes 1996; 45(suppl2):108°
74 Gough A, Abraha H, Purewal TS, et al. Measurement of markers of osteoclast and osteoblastic activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 1997; 14: 527
75 Selby PL, Jude EB, Burgess J, et al. Bone turnover markers in acute Charcot neuroarthropathy. Diabetologia 1998; 41 (Suppl 1): A275
76 Baumhauer J, O’Keefe R, Scjpn L, Pinzur M. Cytokine-induced psteoclastic bone resorption in Charcot arthropathy: An immunohistochemical study. Foot Ankle Int 2006; 27:797-800
77 LaFontaine J, Harkless L, Sylvia V, Carnes D, Heim-Hall J, Jude E. Levels of Endothelial Nitric Oxide Synthase and Calcitonin Gene–related Peptide in the Charcot Foot: A Pilot Study. J Foot Ankle Surg 2008;47:424-429
78 Wahl SM, McCartney-Francis N, Chan J et al. Nitric oxide in experimental joint inflammation. Benefit or detriment. Cells Tissues Organs 2003;174:26-33
79 Huige L, Wallerath T, Forstermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 2002;7:132-147
80 Wahl SM, McCartney-Francis N, Chan J et al. Nitric oxide in experimental joint inflammation. Benefit or detriment. Cells Tissues Organs 2003;174:26-33
81 Li YJ, Peng J. The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. Eur J Pharmacol 2002; 442:173-7
82 Herman S, Müller RB, Krönke G, et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008;58:3041-3050.
83 Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008;10:212
84 Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2002; 4:226-231).
85 Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. 2005 Lancet. 366:2058-61
86 Jostel A, Jude EB. Medical treatment of Charcot neuroarthropathy. Clin Podiatr Med Surg 2008; 25:63
87 Fabrin J, Larsen K, Holstein PE.Long term follow up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000; 23: 796-800
88 Jude EB, Boulton AJM. End stage complications of diabetic neuropathy. Diabetes Rev 1999; 7: 395-410
89 Chantelau E, Schnable T. Palliative radiotherapy for acute osteoarthropathy of diabetic feet: a preliminary study. Pract Diabetes 1997; 14: 154-157
90 Strauss C, Gonya G. Adjunct low intensity ultrasound in Charcot neuroarthropathy. Clin Orthop Relat Res 1998; 349: 132-138
91 Selby PL, Young MJ, Adams JE, Boulton AJM. Bisphosphonate: a new treatment for diabetic Charcot neuroarthropathy. Diabet Med 1994; 11:14-20
92 Fleisch H, Reszka A, Rodan G, Rogers M. Bisphosphonate: mechanism of action. In: Bileizikan JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd edn.San Diego,CA:Academic press; 2002: 1361-1385
93 Schott GD. Bisphosphonate for pain relief in reflex sympathetic dystrophy? Lancet 1997;350:1117.
94 Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients. Acta Oncol Suppl 1996; 35:50-54
95 Anderson JJ, Woelffer KE, Holtzman JJ, Jakobs AM. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 2004; 43: 285-289
96 Pitocco D, Ruotolo V, Caputo S et al. Six month treatment with alendronate in acute Charcot neuroarthropathy: a randomised controlled trial. Diabetes Care 2005; 28: 1214-1215
97 Simon SR, Tejwani SG, Wilson DL, Santner TJ, Denniston NL. Arthrodesis as an early alternative to nonoperative management of Charcot arthropathy of the diabetic foot. J Bone Joint Surg 2000; 82A: 939-950
98 Pinzur MS, Shields N, Trepman E, Dawson P, Evans A. Current practice patterns in the treatment of Charcot foot. Foot Ankle Int Nov 2002; 21: 916-920
99 Sammarco GJ, Conti SF. Surgical treatment of neuroarthropathic foot deformity. Foot Ankle Int 1998;19: 102-109
100 Pinzur MS, Sage R, Stuck R, Kaminsky S, Zmuda A. A treatment algorithm for neuropathic (Charcot) midfoot deformity. Foot Ankle Int 1993; 14: 189-197
101 Harris JR, Brand PW. Patterns of disintegration of the tarsus in the anesthetic foot. J Bone J Surg Br 1966; 48: 4-16
102 Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: the Charcot foot. In: Frykberg RG ed The high risk foot in diabetes mellitus. New York: Churchill-Livingstone, 1990: 297-338
103 Rosemblum BI, Giurini JM, Miller LB et al. Neuropathic ulceration plantar to the lateral column in patients with Charcot foot deformity: a flexible approach to limb salvage. J Foot Ankle Surg 1997; 36: 360-363
104 Pinzur MS, Kelikian A. Charcot ankle fusion with retrograde locked intramedullary nail. Foot Ankle Int 1997; 18:699-704.
105 Caravaggi C, Cimmino M, Caruso S, Dalla Noce S. Intramedullary compressive nail fixation for the treatment of severe charcot deformity of the ankle and rear foot. J Foot Ankle Surg 2006; 45 (1): 20-4.
106 Dalla Paola L, Volpe A, Varotto D, et al: Use of a retrograde nail for ankle arthrodesis in Charcot neuroarthropathy: a limb salvage procedure. Foot Ankle Int 2007; 28 (9): 967-970
107 Lortat-Jacob, A; Beaufils, P; Coignard, S; et al: Tibiotarsal arthrodesis in a septic milieu. Rev Chir Orthop Reparatrice Appar Mot. 70(6):449-56, 1984
108 Thordarson, DB; Patzakis, MJ; Holtom, P; et al: Salvage of the septic ankle
with concomitant tibial osteomyelitis. Foot Ankle Int 18(3): 151-56, 1997
109 Richter, D; Hahn, MP; Laun, RA; et al: Arthrodesis of the infected ankle and subtalar joint: technique, indications, and results of 45 consecutive cases. J Trauma. 47(6):1072-8, 1999
110 Johnson EE, Weltmer J, Lian GJ, et al. Ilizarov ankle arthrodesis. Clin Orthop. 280: 160-9, 1992
111 LoGerfo FW, Gibbons GW, Pomposelli FB Jr, Campbell DR, Miller A, Freeman DV, Quist WC. Trends in the care of the diabetic foot. Expanded role of arterial reconstruction. Arch Surg 1992;127:617-20.
112 Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 29: 854-60.
113 Ouriel K. Peripheral arterial disease. Lancet 2001; 358:1257-64
114 Kansal N, Hamdan A. Clinical features and diagnosis of macrovascular disease. In: The diabetic foot: Medical and surgical Management. Ed A. Veves, JM Giurini, and FW Lo Gerfo, Humana Press Inc, Totowa, NJ, 113-125, 2000
115 Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996; 13 Suppl: S6-11.
116 Emanuele MA, Bauchanan BJ, Abraira C. Elevated leg systolic pressure and arterial calcifications in diabetic occlusive vascular disease. Diabetes Care 1981;4: 289-292
117 Yeager RA, Moneta GL, Edwards JM,Williamson K, McConnell DB, Taylor LM, Porter JM. Predictors of outcome of forefoot surgery for ulceration and gangrene. Am J Surg 1998; 175:388-390
118 TranAtlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease(PAD). Eur J Vasc Endovasc Surg;19 Suppl, 2000
119 European Working Group on critical leg ischemia. Second European consensus on chronic critical leg ischemia. Eur J Vasc Surg 6 Suppl A 1-32, 1992
120 Gibbons GW, Wheelock Fc Jr, Hoar CS Jr, Rowbotham JL, Siembieda C. Predictive success of forefoot amputations in diabetics by noninvasive testing. Arch Surg 1979; 114:1034-1036
121 Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-34
122 Fraser SC, al-Kutoubi MA, Wolfe JH. Percutaneous transluminal angioplasty of the infrapopliteal vessels: the evidence. Radiology. 1996; 200:33-6.
123 Melliere D, Berrahal D, Desgranges P, et al. Influence of diabetes on revascularisation procedures of the aorta and lower limb arteries: early results. Eur J Vasc Endovasc Surg. 1999; 17: 438-41.
124 Spence LD, Hartnell GG, Reinking G, Gibbons G, Pomposelli F, Clouse ME. Diabetic versus nondiabetic limb-threatening ischemia: outcome of percutaneous iliac intervention. AJR Am J Roentgenol. 1999;172:1335-41.
125 Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation. 1994; 89:511-31.
126 Grollman J, Levin DC, Bettmann MA, et al. Recurrent symptoms following lower extremity angioplasty: claudication and threatened limb. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl:95-9.
127 Kumpe DA, Rutheford RB. Percutaneous transluminal angioplasty for lower extremity ischemia. In: Rutheford RB eds Vascular Surgery, 3rd edition. Philadelphia PA : WB Saunders. 1992 : 759-61.
128 London NJ, Varty K, Sayers RD, et al. Percutaneous transluminal angioplasty for lower-limb critical ischemia. Br J Surg. 1995; 82:1232-5.
129 Rhodes JM, Gloviczki P, Bower TC, et al. The benefits of secondary interventions in patients with failing or failed pedal bypass grafts. Am J Surg. 1999;178:151-5.
130 Gschwandtner MF, Minar F, Ahmadi A, et al. Impact of different therapeutic alternatives in treatment of severe limb ischemia: Experiences on 190 consecutive patients at a department of medical angiology. Vasa 1999; 28:271-278.
131 Melki JP, Fermand M, Riche MC, et al. Treatment of diabetic arteriopathy. Importance of transluminal angioplasty. J Mal Vasc 1993;18:37-41.
132 Soder HK, Manninen HI, Jaakkola P, et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000; 11: 1021-31.
133 Wagner HJ, Rager G. Infrapopliteal angioplasty: a forgotten region? Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1998;168:415-20
134 Treiman GS, Oderich Gustavo SC, Ashrafi A, et al. Management of ischemic heel ulceration and gangrene: an evaluation of factors associated with successful healing. J Vasc Surg 2000; 31: 1110-1118
135 Yeager RA, Moneta GL, Edwards JM, Williamson WK, Taylor LM Jr, Porter JM. Predictors of outcome of forefoot surgery for ulceration and gangrene. Am J Surg 1998; 175: 388-390
136 La Fontaine J, Reyzelman A, Rothenberg G, Husain K, Harkless LB. The role of revascularization in transmetatarsal amputations. J Am Podiatr Med Assoc 2001; 91: 533-535
137 Adam DJ, Beard JD, Cleveland T et al. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366: 1925-1934
138 Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHC Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report from the American Association for Vascular Surgery / Society of Vascular Surgery, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHC Task Force on érectice Guidelines (Writing Committee to Develop Guidelines for the management of Patients With Peripheral Arterial Disease).American College of Cardiology Web Site,188.8.131.52 Endovascular treatments for CLI, 65-66, 2005
139 Isner JM, Rosenfield K. Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization. Circulation 1993; 88: 1534-1557
140 Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, Burgess AM, Miller A, LoGerfo FW. Dorsalis pedis arterial bypass: durable limb salvage for foot ischemia in patients with diabetes mellitus. J Vasc Surg; 21: 375-384, 1995.
141 Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG, Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. Ann Vasc Surg 2000; 14: 640-647
142 Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diab Compl 1999; 13:254-263.
143 American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care. Diabetes Care 1999; 22: 1354-60
144 Lipsky BA Infectious problems of the foot in diabetic patients In: Bowker JH, Pfeifer MA (eds): Levin and O’ Neal’s The Diabetic Foot 6th edition Mosby 2001
145 Chantelau E, Tanudjaja T, Altenhofer F. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156-159
146 Boiko EJ, Lipsky BA Infection and diabetes mellitus. In: Harris MI (ed), Diabetes in America, 2nd ed. Diabetes data compiled 1995. Bethesda, MD: National Institutes of Health. NIH publication No 95-1468,1995: 485-499
147 Rosemblum BI, Pomposelli FB. Maximizing foot salvage by a combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. A 5-year experience. Diabetes Care 1994; 9: 983-987
148 Holstein P. Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care 1999; 22: 97-103.
149 Gibbons GW. The diabetic foot: amputations and drainage of infection. J Vasc Surg 1987; 5:791-793
150 Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996; 183:631-641
151 Rodeheaver GT, Pretty D, Thacker JG, et al. Wound cleansing by high pressure irrigation. Surg Gynecol Obstet 1975;141: 357-362
152 Dalla Paola L, Brocco E, Senesi A. et al. Versajet in limb salvage after failed minor amputation in diabetic foot. IV AIUC Congress. Turin 2005.
153 Dalla Paola L, Brocco E, Senesi A, et al. Super-oxidized solution (SOS) therapy for infected diabetic foot ulcers. Wounds 2006; 9: 321-326.
154 Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg 2000; 39: 31-33
155 Epstein DA, Corson JD. Surgical perspective in treatment of diabetic foot ulcers. Wounds 2001; 13: 59-65
156 Edelson GW, Armstrong DG, Lavery LA, Caicco G. The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. Arch Intern Med 1996; 156:2873-2878.
157 Van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004; 39: 123-128.
158 Shape JN. Antibiotics as an adjunct to surgical management of lower extremity ulcerations. Wiley InterScience 14 January 2004
159 Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J. 2004; 1:123-132
160 Sanders LJ. Surgical approach to the diabetic foot. In: Edmonds ME, Foster AVM, Sanders L (Eds.) A practical Manual of Diabetic Footcare, BlacKwell Publishing, 183-219, 2004
161 Tan SJ, Friedman NM, Hazelton Miller C, Flanagan JP,File TM Jr. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation ? Clin Infect Dis 1996; 23:286-291
162 Brandt MM, Corpron CA, Wahl WL. Necrotizing soft tissue infections: a surgical disease. Am J Surg 2000; 66:967-970
163 Landa-Solis C, Gonzalez-Espinoza D, Guzman B, Snyder M, Reyes-Teran G, Torres K, Gutierrez AA. Microcyn: a novel super-oxidized water with neutral pH and disinfectant activity. J Hosp Infect 2005; 61 (4):291-299
164 Wieman TJ. Efficacy and safety of a topical gel formulation of recombinant human-platelet derived growth factor-BB (beclapermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-bind study. Diabetes Care 1998;21(5): 822-7
165 Caravaggi C, De Giglio R, Pritelli C, Sommariva M, et al. HYAFF 11-based dermal and epidermal grafts in the treatment of noninfected plantar and dorsal foot ulcers. Diabetes Care 2000; 10: 2853-59
166 Veves A, Falanga V, Armstrong DG, et al. Apligraf diabetic foot Graftskin, a human skin equivalent, is effective in the management of non-infected neuropathic diabetic foot ulcers: a prospective randomised multi center clinical trial. Diabetes Care 2001; 24: 290-295
167 Richard A. A Human Dermal Replacement for the Treatment of Diabetic Foot Ulcer. Wounds 1997; 9(1):175-183
168 Morykwas M, Argenta L, Shelton-Brown E, McGuirt W. Vacuum- assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plas Surg. 1997; 38; 6: 55-6
169 Kieswetter K. Mechanism of action for NPWT. Presentation at the National VAC Educational Conference. New York, NY: May 2004
170 Joseph E, Hamori C, Bergman S, Roaf E, Swann N, Anastasi G. A prospective randomized trial of vacuum-assisted closure versus standard therapy of chronic nonhealing wounds. Wounds 2000; 12: 60-67
171 Armstrong DG, Attinger CE, Boulton AJ, Frykberg RG, Kirsner RS, Lavery LA, Mills JL. Guidelines regarding negative wound therapy (NPWT) in the diabetic foot. Ostomy Wound Manage 2004 Apr; 50 (4B Suppl): 3S-27S
172 Armstrong DG, Lavery LA et al. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 12: 1704-1710.
173 Donohe ME, Fletton JA, Hook A, et al. Improving foot care for people with diabetes mellitus-a randomized controlled trial of an integrated care approach. Diabet Med 2000; 17:581-7
174 Driver VR, Madsen J, Goodman RA. Reducing amputation rates in patients with diabetes at a military medical center: the limb preservation service model. Diabetes Care 2005; 28: 248-53
175 Gottrup FA. Specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004; 187: 38-43
176 Wright PR, Lawrence SM, Campbell DA, et al. Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabet Med. 22:127-36. 2005